NYSE:CRXM
Delisted

Taxus Cardium Pharmaceuticals Group, Inc Stock Forecast

$0.000001
+0 (+0%)
At Close: Nov 10, 2022
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

FAQ

What is the symbol for Taxus Cardium Pharmaceuticals Group, Inc Stock and on which exchange is it traded?
The symbol for Taxus Cardium Pharmaceuticals Group, Inc is CRXM and it is traded on the NYSE (New York Stock Exchange).

Should I buy or sell Taxus Cardium Pharmaceuticals Group, Inc Stock?
Taxus Cardium Pharmaceuticals Group, Inc holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Taxus Cardium Pharmaceuticals Group, Inc Stock?
Taxus Cardium Pharmaceuticals Group, Inc Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Taxus Cardium Pharmaceuticals Group, Inc Stock.

What's the current price of Taxus Cardium Pharmaceuticals Group, Inc Stock?
As of the end of day on the 2022-11-10, the price of an Taxus Cardium Pharmaceuticals Group, Inc (CRXM) share was $0.000001.

What is the 52-week high and low for Taxus Cardium Pharmaceuticals Group, Inc Stock?
The 52-week high for Taxus Cardium Pharmaceuticals Group, Inc Stock is $0.0001 and the 52-week low is $0.000001.

What is the market capitalization of Taxus Cardium Pharmaceuticals Group, Inc Stock?
As of the 2022-11-10, the market capitalization of Taxus Cardium Pharmaceuticals Group, Inc is 65.
Click to get the best stock tips daily for free!

About Taxus Cardium Pharmaceuticals Group, Inc

Taxus Cardium Pharmaceuticals Group Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced ... CRXM Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT